Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | NEK2 | P51955 | 1/20 | 0.52 |
| ▸ | STK3 | Q13188 | 1/20 | 0.52 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.52 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323359 | 0.86 | CHEK1 (0.74) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13156340 | 0.86 | CHEK1 (0.78) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13156307 | 0.79 | CHEK1 (0.74) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13322864 | 0.78 | CHEK1 (0.78) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13954643 | 0.78 | CHEK1 (0.65) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13156341 | 0.77 | CHEK1 (1.00) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13322868 | 0.77 | CHEK1 (0.73) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13156345 | 0.76 | CHEK1 (0.94) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL13322996 | 0.73 | CHEK1 (0.64) | CHEK1JAK2ROCK2IGF1RMAPK1 | |
| SCHEMBL16519601 | 0.72 | CHEK1 (0.87) | CHEK1JAK2ROCK2IGF1RMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | CHEK1 61/4885JAK2 2406/4885ROCK2 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.